A Dynamic, Split-Luciferase-Based Mini-G Protein Sensor to Functionally Characterize Ligands at All Four Histamine Receptor Subtypes

Carina Höring *, Ulla Seibel, Katharina Tropmann, Lukas Grätz, Denise Mönnich, Sebastian Pitzl, Günther Bernhardt, Steffen Pockes and Andrea Strasser *

Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany; ulla.seibel@ur.de (U.S.); katharina.tropmann@ur.de (K.T.); lukas.graetz@ur.de (L.G.); denise.moennich@ur.de (D.M.); sebastian.pitzl@ur.de (S.P.); guenther.bernhardt@ur.de (G.B.); steffen.pockes@ur.de (S.P.)

* Correspondence: carina.hoering@ur.de (C.H.); andrea.strasser@ur.de, (A.S.);
  Tel.: +49-941-943-4748 (C.H.); +49-941-943-4821 (A.S.)

Received: 3 October 2020; Accepted: 8 November 2020; Published: 10 November 2020

Abstract: In drug discovery, assays with proximal readout are of great importance to study target-specific effects of potential drug candidates. In the field of G protein-coupled receptors (GPCRs), the determination of GPCR-G protein interactions and G protein activation by means of radiolabeled GTP analogs ([35S]GTPγS, [γ-32P]GTP) has widely been used for this purpose. Since we were repeatedly faced with insufficient quality of radiolabeled nucleotides, there was a requirement to implement a novel proximal functional assay for the routine characterization of putative histamine receptor ligands. We applied the split-NanoLuc to the four histamine receptor subtypes (H₁R, H₂R, H₃R, H₄R) and recently engineered minimal G (mini-G) proteins. Using this method, the functional response upon receptor activation was monitored in real-time and the four mini-G sensors were evaluated by investigating selected standard (inverse) agonists and antagonists. All potencies and efficacies of the studied ligands were in concordance with literature data. Further, we demonstrated a significant positive correlation of the signal amplitude and the mini-G protein expression level in the case of the H₂R, but not for the H₁R or the H₃R. The pEC₅₀ values of histamine obtained under different mini-G expression levels were consistent. Moreover, we obtained excellent dynamic ranges (Z’ factor) and the signal spans were improved for all receptor subtypes in comparison to the previously performed [35S]GTPγS binding assay.

Keywords: histamine receptors; split-luciferase complementation (SLC); mini-G protein recruitment; G protein-coupled receptors (GPCRs); histamine receptor ligands; bioluminescence

1. Introduction

G protein-coupled receptors (GPCRs) transduce external stimuli to intracellular events by the activation of heterotrimeric G proteins. Upon receptor activation, the heterotrimeric G protein binds to the receptor, which is followed by a GDP-GTP nucleotide exchange at the Gα subunit. The resulting conformational change of Gα promotes the uncoupling of the G protein from the receptor and the dissociation of the heterotrimer into a Gα monomer and a Gβγ dimer [1,2]. Both are then capable to modulate effector proteins inside the cell. Canonical GPCR-mediated signaling is determined by Gα, the subtypes of which target different membrane-bound effectors, such as phospholipase C [3,4] (PLC) and adenyl cyclase [5,6] (AC). In drug discovery, GPCRs are the most studied drug targets and are addressed by more than 30% of approved drugs [7]. Fundamental criteria for successful drugs are a high binding affinity and potency at the target receptor, as well as a distinct pharmacological action ((full,
partial, inverse) agonism, antagonism). The further downstream in the signaling cascade, the more pronounced the signal, irrespective of the ultimate cellular response. Thus, the characterization of the proximal functional response as a target-specific effect is desirable, particularly for lead-structure identification and bias analysis of compounds.

Classical methods have successfully focused on the key events of receptor-G protein interaction and G protein activation using radiolabeled GTP analogs ([35S]GTPγS [8–10], [γ-32P]GTP [11–13]). Unfortunately, we have repeatedly experienced insufficient quality with batches of commercially available radiolabeled GTP analogs. For this reason, compounded by economic considerations, such as the increased cost of radioactive waste disposal, it may be preferable to implement a different proximal functional assay, both for routine testing and detailed pharmacological studies of ligand-GPCR interaction. Non-radioactive labels of GTP analogs, such as europium [14], TAMRA, Cy3, and Cy5 [15], as well as the utilization of the commercial GTPase-Glo™ technique [16], in which native GTP is converted to ATP, which is then involved in an enzyme reaction, allow for a fluorescent or bioluminescent readout. However, these methods are restricted to membrane preparations, cell homogenates or fixed cells [16,17]. Moreover, nucleotide exchange and GTP hydrolysis represent limiting steps according to the respective Gα subtype [18]. Modern FRET-/BRET-based G protein activation sensors monitoring the interaction of appropriate donor-acceptor pairs (GPCR and Gα/Gβγ [19], Gα and Gβγ [20] or Gβγ and a membrane anchor [21]) provide valuable insight into signaling kinetics and can visualize signal compartmentalization. However, for routine characterization of potential ligands, the application of these sensors is unfavorable due to the requirement for specialized equipment (e.g., multiple wavelength monitoring) and comprehensive expertise in performing the time-sensitive technique (millisecond timescale). Additionally, the spectral properties of the donor/acceptor pairs (intensity and spectral overlap of the excitation and emission wavelengths) can affect the signal amplitude [18]. This is an issue in case of weakly expressed GPCRs.

In 2017, a new class of minimal G protein chimeras (mini-G) was developed. All mini-G constructs are surrogates of the Gαs subunit and comprise the following key features: minimization to the GTPase domain, a mutation that uncouples the binding to active state GPCRs from nucleotide exchange, and the deletion of the N-terminal membrane anchor as well as the Gβγ binding site. By replacing the α5 helix of the minimal Gαs protein (mGs) with the respective sequence of other Gα subunits, mini-G proteins covering all major Gα families were derived and appropriate coupling specificities were demonstrated [22]. The application of BRET and split-luciferase complementation (SLC) techniques to GPCRs and mini-G proteins has created new G protein sensors that monitor functional responses in real-time [23–27]. Of particular note, the dynamic assay ranges benefited from the cytosolic nature of the mini-G proteins, as native, membrane-anchored G proteins produce high baseline values due to their closer proximity to membrane-bound GPCRs [23–25].

The aim of this study was to implement a modern, live cell-based assay to study the molecular signaling mechanisms of putative histamine receptor agonists and antagonists. Moreover, the method needed to provide a proximal readout with improved signal amplitudes, which was essential for the weakly expressed H4R [28]. For these purposes, the mini-G protein concept was considered suitable. We applied the split-NanoLuc technology [29] to the human histamine receptor subtypes H1, H2, H3 or H4 (NlucC) and
the corresponding mini-G proteins mGsq, mGs and mGsi (NLucN) (Supplementary Figure S1). Upon receptor activation, the mini-G protein was recruited by the receptor leading to the formation of a functional NanoLuc (Figure 1A). Thus, agonist concentration-dependent luminescence signals were obtained in the presence of the substrate furimazine (Figure 1B). To investigate antagonists, the response of the reference agonist histamine at EC$_{80}$ concentration (H$_1$R: 10 µM, H$_2$–4R: 1 µM) was measured after a pre-incubation period of the respective antagonists. In order to verify the histamine receptor expression, radioligand saturation binding experiments were performed, and adequate binding of [3H]mepyramine to the H$_1$R co-expressed with mGsq, [3H]UR-DE257 to the H$_2$R co-expressed with mGs and [3H]UR-PI294 to the H$_3$R and H$_4$R each co-expressed with mGsi were observed (Supplementary Figure S2 and Table S1).

Figure 1. Principle of the mini-G protein recruitment assay and obtained signals at the H$_{1–4}$R. (A) Scheme of the mini-G protein recruitment assay. The split-NanoLuc technology was applied to the H$_{1–4}$R (C-terminus) and the mini-G proteins (mG; N-terminus). Upon receptor activation, the mini-G protein is recruited to the GPCR and the split-NanoLuc fragments form a functional enzyme leading to the oxidation of the substrate and thus luminescence signals in an agonist concentration-dependent manner. (B) Representative luminescence traces of the mini-G protein recruitment of mGsq to H$_1$R, mGs to H$_2$R and mGsi to H$_3$R and H$_4$R. Baseline and inter-well corrected luminescence traces of histamine at various concentrations and the assay medium Leibovitz’s L-15 (L-15) as negative control are plotted. (C) Plotted signal-to-background ratios (S/Bs) were calculated from 100% and 0% values of the respective assays, representing top and bottom values of the concentration response curves. For the mini-G recruitment assay (mG), peak or plateau values of the response to 100 µM histamine (100%) and L-15 (0%) are displayed, whereas for the [35S]GTPγS binding assay (GTPγS) responses to 1 mM histamine for H$_{1,2}$R or to 10 µM histamine for H$_{3,4}$R (100%) and H$_2$O (0%) were taken. Presented data are the means ± SEM of at least five independent experiments (n ≥ 5), each performed in triplicate.

2.2. Kinetics and Dynamic Ranges of Mini G Protein Recruitment

The dynamic split-NanoLuc approach allows for monitoring the G protein response to a ligand in real-time, demonstrating the differences in kinetics for each receptor and mini-G protein combination upon histamine stimulation (Figure 1B). The mGsq recruitment to the H$_1$R is comparatively slow, leading to a plateau, whereas the luminescence signals of the mGs and mGsi recruitment to the H$_2$R, H$_3$R and H$_4$R reach very sharp maxima and then flatten gradually. As the deletion of the membrane anchor and the Gβγ binding site were key modifications in the development of the utilized mini-G proteins, we assume that these observed kinetics will differ to the behavior of endogenous heterotrimeric G proteins. Further, other properties of the test system, such as the split-luciferase complementation reaction and the protein expression levels of the receptors and mini-G proteins, could influence the kinetics. Nevertheless, tracing the mini-G protein recruitment upon receptor activation in real-time could unveil differences in receptor regulation (e.g., receptor desensitization and
internalization) [30,31] and may also serve as a useful tool to supplement studies of ligand binding kinetics, such as association and dissociation rate constants (k_{on/off}) and residence time [32,33].

Using the mini-G sensors, the signal amplitudes of the assay were improved for all four receptor subtypes compared to the [35S]GTPγS binding assay (Figure 1C). For uniform comparison of the signal-to-background (S/B) ratios, we also implemented the [35S]GTPγS binding assay for the H1R (Table S1, Supplementary Methods). Remarkably, in the case of the H1R, the S/B ratio was up to 29-fold higher in the mini-G protein recruitment assay than in the [35S]GTPγS binding assay (Figure 1C). Such favorable S/Bs are beneficial for the determination of agonist efficacies and will allow for a reduction of the agonist concentration when exploring antagonists. To evaluate the overall assay quality, we calculated the Z' factor, a dimensionless figure of statistical effect size. Classically, the Z' factor has been used in the validation process of HTS methods, as it numerically evaluates the dynamic range of an assay and its ability to identify biologically active molecules [34]. For all four receptor subtypes, we obtained a Z' factor that was between 0.5 and 1.0 (H1R: 0.79 ± 0.07, H2R: 0.85 ± 0.03, H3R: 0.80 ± 0.04, H4R: 0.68 ± 0.05; Supplementary Figure S3) indicating a sufficient separation of maximal effect and baseline values. Consequently, the presented mini-G protein recruitment assays can be classified as excellent screening methods [34].

2.3. Mini-G Protein Recruitment-Based Investigation of Histamine Receptor Ligands with Diverse Pharmacological Profiles

To demonstrate the applicability of these novel assays for future drug research, we tested a set of standard ligands (Supplementary Figure S4), which are described as (inverse) agonists or antagonists. We experienced a broad range of potencies and efficacies for ligands at all four receptor subtypes (Figure 2) and the order of potencies of all studied agonists was in good agreement with literature data (Figure 2A, Tables 1–4). However, as general observation, agonists probed at the H3R and the H4R displayed lower potencies (up to one magnitude) than in published [35S]GTPγS binding and steady-state GTPase activity assays (cf. Tables 3 and 4). Likewise, this phenomenon was observed for agonists studied in NanoBRET binding assays using intact cells expressing either the H2R or the H3R, as well as for agonists investigated with a H3R conformational sensor [35–37]. This finding was proposed as a consequence of an altered GPCR-G protein-guanine nucleotide composition, and therefore a more transient formation of the ternary complex compared to cell membrane preparations or cell homogenates [17]. By testing a large set of agonists, we validated the mini-G protein recruitment approach to report on a multifaceted spectrum of pharmacological actions. Efficacies ranged from weak partial agonism, discovered for histaproifen at the H1R (E_{max} = 33% ± 2.0) and UR-PI294 at the H1R (E_{max} = 29% ± 1.4) and H3R (E_{max} = 11% ± 1.1), to full agonism, demonstrated by e.g., Nα-methylhistamine at the H1R (E_{max} = 99% ± 2.0), dimaprit at the H2R (E_{max} = 94% ± 2.6) and histamine (by definition: 100%) at all four receptor subtypes (Tables 1–4). Strikingly, the efficacies of UR-KUM530 at the H1R (E_{max} = 112 ± 1.0) and Nα-methylhistamine at the H3R (E_{max} = 111 ± 1.6) were significantly higher (α < 0.05) as those of the endogenous ligand histamine (Tables 1 and 3), which is hypothesized as “superagonism” [38]. Similar results were previously observed for UR-KUM530 and were suggested to originate from a differing orientation in the binding pocket of the H1R compared to histamine [39,40]. In contrast, Nα-methylhistamine has always been reported as a full agonist at the H3R [8].

Additionally, we extended the application of the mini-G sensor to the characterization of antagonists. The cells expressing the histamine receptors in combination with the respective mini-G proteins were pre-incubated with the antagonists and the response to the subsequently added agonist histamine was assessed. In this setting, standard antagonists exhibited expected pKb values at all receptor subtypes (Figure 2B, Tables 1–4). Only in the cases of the tricyclic H1R antagonists maprotiline (pKb = 10.58 ± 0.11) and cyprophedrine (pKb = 10.19 ± 0.10), we determined up to two magnitudes higher pKb values than reported (Table 1). In the past, histamine receptors were reported to be constitutively active [41] in recombinant systems [42–45]. Investigation of the inverse
agonistic potential of antagonists revealed that nearly all antagonists reduced the basal activity of the histamine receptors in the mini-G protein recruitment assay in a concentration-dependent manner (Figure 2C, Tables 1–4). However, in our system the maximal inverse efficacies were small (H₁R: −4%, H₂R: −8%, H₃R: −3%, H₄R: −8% normalized to 100 µM histamine). Contrary to the literature, the constitutive activity of the Gαᵢ-coupled receptors H₃R and H₄R was less pronounced [10,46]. However, as thioperamide demonstrated inverse agonism at the H₄R, we confirmed JNJ7777120 and A943931 as neutral H₄R antagonists.

Figure 2. Concentration response curves obtained in the mini-G protein recruitment assay using agonists (A) in agonist mode, as well as antagonists in antagonist mode (B) and agonist mode (C). In agonist mode, the effect of the ligands themselves was tested, whereas experiments in antagonist mode were performed in the presence of the agonist histamine (H₁R: 10 µM, H₂–4R: 1 µM). HEK293T cells stably co-expressing a combination of either the H₁R-NlucC/ NlucN-mGsq, H₂R-NlucC/ NlucN-mGs, H₃R-NlucC/ NlucN-mGsi or H₄R-NlucC/ NlucN-mGsi were used. Data were normalized to L-15 as solvent control and to maximal responses elicited by 100 µM histamine in the case of agonists, 10 µM histamine for H₁R antagonists or 1 µM histamine for H₂–4R antagonists. Data represent means ± SEM from at least three independent experiments (n ≥ 3), each performed in triplicate.
Table 1. Potencies (pEC50/pKb) and efficacies (E_{max}) of ligands at the H1R explored in the mini-G protein recruitment assay. Data represent means ± SEM of at least three independent experiments (n ≥ 3), each performed in triplicate. Statistical differences (*) of E_{max} > 100% was tested using a one-sample t-test (n = 5; α = 0.05). Functional data obtained from [35S]GTPγS and steady-state GTPase assays and ligand binding affinities (pK_i) determined in radioligand competition binding assays are included for comparison.

| Compound | Mini G Protein Recruitment | GTPγS/GTPase ‡ | Competition Binding |
|----------|-----------------------------|-----------------|---------------------|
|          | pEC50/pKb | E_{max} [%] | pEC50/pKb | E_{max} [%] | pK_i |
| his      | 6.16 ± 0.09 | 100 | 5.21 ± 0.06 a | 6.92 ± 0.1 b | 100 a | 5.62 h |
| KUM530   | 6.41 ± 0.12 | 112 ± 1.0 * | 6.22 ± 0.10 a | 7.75 ± 0.1 c | 95 ± 5.7 | 94 c |
| betahis  | 5.49 ± 0.13 | 75 ± 2.0 | 5.84 ± 0.1d | 86 ± 4.1d | 86.1 |
| histapro | 6.39 ± 0.03 | 33 ± 2.0 | 5.86 ± 0.07 a | 6.95 ± 0.1 b | 31 ± 2.8 | 62.1 b |
| Namh     | 5.56 ± 0.08 | 99 ± 2.0 | 4.80 ± 0.1e | 90 ± 0.1e | 4.80 ± 0.1 e |
| 4mhis    | 4.46 ± 0.16 | 44 ± 2.4 | 5.46 ± 0.1f | 64 ± 0.1b | 6.58 h |
| P294     | 4.93 ± 0.03 | 29 ± 1.4 | 5.46 ± 0.1f | 64 ± 0.1b | 6.58 h |
| supralis | 6.09 ± 0.13 | 49 ± 3.7 | 6.83 ± 0.1b | 6.83 ± 0.1b | 6.83 h |
| dph      | 6.95 ± 0.04 | (6.69) ± 0.17 | 6.98 ± 0.07 a | (7.81) ± 0.14 | 7.40 |
| map      | 8.51 ± 0.04 | (10.58) ± 0.11 | 8.51 ± 0.04 | (10.58) ± 0.11 | 8.51 |
| mep      | 8.36 ± 0.11 | (8.54) ± 0.19 | (8.25) ± 0.14 | (8.25) ± 0.14 | 8.39 |
| cyp      | 8.68 ± 0.24 | (10.19) ± 0.10 | 8.72 ± 0.14 | (8.72) ± 0.14 | 8.72 |

Reference data are taken from (unless otherwise stated, E_{max} values refer to histamine = 100%): a functional [35S]GTPγS binding assays using S9′ cells co-expressing either hH1R, Goαq, Goβ1 and Goγ2; b functional [32P]GTPase activity assays using membrane preparations of S9′ cells co-expressing hH1R and RGS4 (k [12], l [40], d [47], e [48], f [49], g [50], h [47], i [48], j [49], k [50]). h [3H]mepyramine displacement assays using S9′ cells co-expressing hH1R and RGS4 (k [12], l [40]). i [3H]mepyramine displacement assays using HEK293 hH1R CRE-Luc cells expressing hH1R (k [39]). j [3H]mepyramine displacement assays using whole cell homogenates of COS-7 cells expressing hH1R (k [51]).

Table 2. Potencies (pEC50/pKb) and efficacies (E_{max}) of ligands at the H2R explored in the mini-G protein recruitment assay. Data represent means ± SEM of at least three independent experiments (n ≥ 3), each performed in triplicate. Functional data obtained in steady-state GTPase assays and ligand binding affinities (pK_i) determined in radioligand competition binding assays are included for comparison.

| Compound | Mini G Protein Recruitment | GTPase | Competition Binding |
|----------|-----------------------------|--------|---------------------|
|          | pEC50/pKb | E_{max} [%] | pEC50/pKb | E_{max} [%] | pK_i |
| his      | 6.94 ± 0.05 | 100 | 6.00 a | 100 a | 6.27 d |
| impro    | 7.48 ± 0.01 | 90 ± 1.5 | 6.80 a | 82 a | 6.31 e |
| amt      | 7.57 ± 0.08 | 105 ± 2.8 | 6.72 a | 85 a | 6.61 d |
| dim      | 6.47 ± 0.04 | 94 ± 2.6 | 6.04 a | 91 a | 4.6 e |
| Namh     | 6.76 ± 0.09 | 93 ± 1.7 | 5.54 b | 101 b | 5.61 f |
| 4mhis    | 6.37 ± 0.05 | 93 ± 2.2 | 5.54 b | 101 b | 5.61 f |
| P294     | 6.92 ± 0.13 | 95 ± 1.1 | 6.43 e | 83 e | 6.31 f |
| cim      | 6.02 ± 0.04 | (6.28) ± 0.02 | (5.77) a | (5.77) a | 6.2 e |
| fam      | 7.29 ± 0.10 | (8.14) ± 0.09 | (7.32) a | (7.32) a | 7.8 e |
| ran      | 7.02 ± 0.11 | (6.99) ± 0.01 | (6.08) a | (6.08) a | 7.1 e |

Reference data are taken from (unless otherwise stated, E_{max} values refer to histamine = 100%): a functional [32P]GTPase activity assays using membrane preparations of S9′ cells expressing a hH2R-Gαq fusion protein (k [11], l [40], k [49], j [48], i [47], i [48], j [49], l [50], h [11], g [49], f [48], e [47]). i [3H]UR-DE257 displacement assays using membrane preparations of S9′ cells expressing a hH2R-Gαq fusion protein (l [52], h [53], j [54]).
Table 3. Potencies (pEC50/pKd) and efficacies (E_{max}) of ligands at the H3R explored in the mini-G protein recruitment assay. Data represent mean values ± SEM of at least three independent experiments (n ≥ 3), each performed in triplicate. Statistical differences (*) of E_{max} > 100% was tested using a one-sample t-test (n = 5; α = 0.05). Functional data obtained in [35S]GTPγS and steady-state GTPase assays and ligand binding affinities (pK_i, pK_d) determined in radioligand competition/saturation binding assays are included for comparison.

| Compound | Mini G Protein Recruitment | GTPγS/GTPase | Competition Binding |
|----------|----------------------------|--------------|---------------------|
|          | pEC_{50}(pK_d) | E_max [%] | pEC_{50}(pK_d) | E_max [%] | pK_i/pK_d |
| his      | 6.47 ± 0.04   | 100        | 7.3 ± 0.04  | 89 ± 0.04 | 7.96 ± 0.04 |
| imet     | 8.30 ± 0.17   | 67 ± 0.7   | 8.6 ± 0.04  | 80 ± 0.04 | 8.8 ± 0.06 |
| immep    | 8.77 ± 0.05   | 63 ± 1.3   | 8.8 ± 0.04  | 77 ± 0.04 | 9.3 ± 0.04 |
| VUF8430  | 5.21 ± 0.12   | 43 ± 1.6   | 6.0 ± 0.04  |           |           |
| Namh     | 7.20 ± 0.03   | 111 ± 1.6  | 7.9 ± 0.04  | 100 ± 0.04 | 8.4 ± 0.06 |
| 4mhis    | 4.53 ± 0.08   | 19 ± 1.5   |           |           |           |
| PI294    | 8.40 ± 0.06   | 11 ± 1.1   | 8.80 ± 0.04 | 39 ± 0.04 | (8.96) ± 0.04 |
| thio     | 7.41 ± 0.04   | (7.21) ± 0.07 | −3 ± 0.4  | 6.9 ± 0.04  | −52 ± 0.04 | 7.42 ± 0.04 |
| clob     | 9.05 ± 0.10   | (9.28) ± 0.12 | −3 ± 0.2  | 9.14 ± 0.01  | −137 ± 1.0  | 9.34 ± 0.04 |
| JNJ      | (5.44) ± 0.01 |           |           |           |           |
| pito     | (8.41) ± 0.05 | (9.80) ± 0.04 |           |           | 5.29 ± 0.04 |

Reference data are taken from (unless otherwise stated, E_{max} values refer to histamine = 100%): a functional [35S]GTPγS binding assays using membrane preparations of HEK293 cell expressing the hH3R (data normalized to (R)-α-methylhistamine (α = 100%) and ABT-229 (α = −100%) (7 10]). b,c,d functional [35P]GTPγS activity assays using membrane preparations of S9 cells co-expressing hH3R, Gα2 and Gβ1γ2 (6 49), e functional [35S]GTPγS binding assays using membrane preparations of CHO cells expressing the hH3R (8 59). t Steady-state GTPase activity assays using membrane preparations of S9 cells co-expressing hH3R, Gα2 and Gβ1γ2 (57). c,d,e [35S]Nα-methylhistamine displacement assays using whole cellular homogenates of SK-N-MC cells expressing the hH3R (5, 54, 55, 58). f [35S]IUR-PI294 saturation binding binding assay using membrane preparations of S9 cells co-expressing hH3R, Gα2 and Gβ1γ2 (57). g, [3H]Iodoprocyanidin displacement assay using whole cellular homogenates of CHO cells expressing the hH3R (5, 58).

Table 4. Potencies (pEC50/pKd) and efficacies (E_{max}) of ligands at the H4R explored in the mini-G protein recruitment assay. Data represent mean values ± SEM of at least three independent experiments (n ≥ 3) each performed in triplicate. Functional data obtained in proximal [35S]GTPγS and steady-state GTPase and ligand binding affinities (pK_i, pK_d) determined in radioligand competition/saturation binding assays are included for comparison.

| Compound | Mini G Protein Recruitment | GTPγS/GTPase | Competition Binding |
|----------|----------------------------|--------------|---------------------|
|          | pEC_{50}(pK_d) | E_max [%] | pEC_{50}(pK_d) | E_max [%] | pK_i/pK_d |
| his      | 6.40 ± 0.04   | 100        | 7.60 ± 0.04  | 100 ± 0.00 | 7.8 ± 0.04 |
| imet     | 6.94 ± 0.04   | 47 ± 0.1   | 8.17 ± 0.04  | 69 ± 0.04 | 8.2 ± 0.04 |
| immep    | 6.73 ± 0.05   | 66 ± 2.8   | 7.35 ± 0.04  | 68 ± 0.04 | 7.7 ± 0.04 |
| VUF8430  | 6.47 ± 0.03   | 60 ± 0.2   | 7.42 ± 0.04  | 84 ± 0.04 | 7.5 ± 0.04 |
| Namh     | 5.68 ± 0.06   | 82 ± 1.1   |           |           | 6.5 ± 0.04 |
| 4mhis    | 6.48 ± 0.06   | 78 ± 0.5   | 7.15 ± 0.04  | 90 ± 0.04 | 7.3 ± 0.04 |
| PI294    | 7.71 ± 0.04   | 85 ± 0.6   | 8.35 ± 0.04  | 102 ± 0.04 | (8.29) ± 0.04 |
| thio     | 7.28 ± 0.06   | 48 ± 2.0   | 7.65 ± 0.04  | 45 ± 0.04 | 7.75 ± 0.04 |
| clob     | 6.68 ± 0.04   | (6.90) ± 0.01 | −8 ± 1.9  | 6.58 ± 0.04  | −139 ± 0.0  | 6.9 ± 0.04 |
| JNJ      | (7.25) ± 0.02 | 0 to 2.8   | 7.10 ± 0.04  | (7.60) ± 0.04 | −39 ± 0.0  | 7.52 ± 0.04 |
| A943931  | (8.43) ± 0.22 | −4 to 2.8  | 7.3 ± 0.04  | −180 ± 0.04 | 8.33 ± 0.04 |

Reference data are taken from (unless otherwise stated, E_{max} values refer to histamine = 100%): a,b,c,d,e,f,g,h,i,j,k,l,m,n,o, p,q,r,s,t,u,v,w,x,y,z functional [35S]GTPγS binding assays using membrane preparations of SK-N-MC cells expressing the hH3R (7 54). i,j [3H]IUR-PI294 saturation binding (7 54) and displacement (7 54) assays using membrane preparations of S9 cells co-expressing hH3R, Gα2 and Gβ1γ2 (7 57). j,j [3H]histamine displacement assays using whole cellular homogenates of SK-N-MC cells expressing the hH3R (7 58).
2.4. Influence of Mini-G Protein Co-Expression on Potencies and Dynamic Ranges

Mini-G proteins functionally mimic active Gα subunits and thus a mutual cooperativity between mini-G protein and agonist binding to GPCRs has been proposed [23]. We probed histamine at the H1-3 receptors co-expressed with increasing mini-G protein levels, but not at the H2R due to its weak transient expression. HEK293T cells were transiently transfected with constant receptor DNA amounts (1 µg) and increasing mini-G DNA amounts (0.125, 0.25, 0.5 and 1.0 µg) and were tested in the mini-G protein recruitment assay with histamine. In all three setups, the transfection of increasing mini-G gene doses were correlated with mini-G protein expression levels, which was demonstrated by a Western blot analysis (Supplementary Figure S5). In the mini-G protein recruitment assay, pEC50 values of histamine were not significantly shifted (α = 0.05) by increasing mini-G expression levels at the three receptor subtypes (Figure 3A,B) in contrast to suggestions of Wan et al. (2018) [23]. However, the signal amplitudes were affected differently for the three receptor/mini-G pairs. In the case of the H1R, the signal span was not altered by different mGsq expression levels (Figure 3A,C). On the contrary, the mGsi expression level determined by the highest gene dose of 1 µg significantly decreased the dynamic range at the H2R and, even more striking, all applied mGs gene doses in rising order led to significantly lowered dynamic ranges at the H2R (α = 0.05; Figure 3A,C). Similar to the collision coupling model of GPCR–G protein interaction [19,63], a possible explanation for the decreased signal amplitudes is that the basal activity of the histamine receptors increase due to higher mini-G expression levels and, thus, a more likely collision of constitutively active receptors and the respective mini-G protein. However, one has to be careful judging the extent of the signal span reduction observed for the H1R/mGsq, H2R/mGs and H3R/mGsi pairs, as e.g., same gene doses of mGsq led to considerably lower expression levels compared to mGs in the Western blot analysis (Supplementary Figure S5) [23].

![Figure 3](https://via.placeholder.com/150)

**Figure 3.** Concentration response curves and functional parameters obtained in the mini-G protein recruitment assay with different mini-G protein expression levels. (A) Concentration response curves, (B) pEC50 values and (C) AUCs of histamine obtained in the mini-G recruitment assay using HEK293T cells transiently transfected with indicated DNA amounts (in µg) of the H1-3R-NlucC and NlucN-mGsq/mGs/mGsi constructs 72 h prior to the experiments. Presented data are from five independent experiments (n = 5), each performed in triplicate. Whiskers (B) represent 95% confidential intervals. Significance levels (C) were calculated using one-way ANOVA followed by Tukey’s multiple comparison test calculated as **p < 0.01, ***p < 0.005, ****p < 0.0001.
2.5. Stabilization of the Active H₂R Conformation by the Minimal G₃ Protein

As the signal amplitude at the H₂R could be correlated to the mGs expression (Figure 3), we further explored binding properties of the endogenous agonist histamine and the antagonist famotidine by displacement of [³H]UR-DE257 at HEK293T cells stably expressing the NlucN-mGs and H₂R-NlucC fusion proteins (Figure 4A, Supplementary Table S2). Whereas the radioligand displacement by famotidine followed a monophasic curve supporting a one-site binding model (pKᵢ = 7.68 ± 0.01), notably a two-sites binding model was preferred for the agonist histamine (pKᵢ,low = 3.87 ± 0.13; pKᵢ,high = 6.94 ± 0.14). Thus, we assumed there was a high affinity binding site at the H₂R as previously described for the ternary H₂R-G protein complex [53]. To correlate the observation to the amount of co-expressed mGs, we probed the binding of histamine at the H₂R by transient transfections of increasing mGs gene doses (from 0 µg to 1 µg of mGs DNA) and a constant gene dose of H₂R (1 µg; Figure 4B, Supplementary Table S2). The expression of the H₂R alone (0 µg of mGs DNA) led to a rightward shifted, but monophasic concentration response curve of histamine. In contrast, by increasing mGs gene doses, we recorded an extended formation of the high affinity binding site (Figure 4B, Supplementary Table S2). Therefore, we deduce that mGs stabilizes the active conformation of the H₂R in a concentration-dependent manner. Although endogenously expressed G proteins are also intended to stabilize active receptor conformations, we did not detect a high affinity binding site using HEK293T cells that were transiently transfected with the H₂R alone. On the one hand, this could be traced back to the lower native expression levels of G proteins compared to the overexpressed mGs. On the other hand, mGs constitutes the active GTPase domain of Gₓ and therefore is immediately accessible for binding to the H₂R in active state, whereas endogenous G proteins presumably exist in diverse conformations [53].

![Figure 4](image)

**Figure 4.** Comparison of radioligand displacement curves at cells co-expressing the H₂R and mGs. (A) [³H]UR-DE257 (50 nM) was displaced by either histamine or famotidine. Presented data are means ± SEM of three independent experiments (n = 3), each performed in triplicate using HEK293T cells stably co-expressing the H₂R-NlucC and NlucN-mGs constructs. (B) Displacement of [³H]UR-DE257 (50 nM) by histamine using HEK293T cells transiently transfected with indicated DNA amounts (in µg) of the H₂R-NlucC and NlucN-mGs constructs 72 h prior to the experiments. Presented data are means ± SEM of three independent experiments (n = 3), each performed in duplicate.

3. Discussion

Our study focused on the development of a novel live cell assay that reports on functional properties of histamine receptor ligands at an early stage of signal transduction. We achieved this by applying the split-NanoLuc to the four histamine receptors and minimal (chimeric) G proteins. We observed excellent signal amplitudes at all four receptor subtypes, which was of particular importance for the weakly expressed recombinant H₄R. Moreover, we are the first to provide time-resolved courses of agonist-mediated functional responses using mini-G sensors with split-NanoLuc complementation for an entire receptor family, the subtypes of which couple to three different types of mini-G proteins (mGs, mGsi and mGsq). As the presented biosensor is becoming...
available for an increasing number of GPCRs [23–27], it will be appealing to extend the application in prospective studies to analyse time-resolved differences of distinct GPCRs coupling to the same minimal G protein. The methodology could also be used to investigate one GPCR coupling to different minimal G proteins (coupling specificity), and to supplement ligand binding studies with kinetic input, for example association and dissociation rate constants \( k_{\text{on/off}} \) and residence time \([32,33]\). This might contribute to an even better pharmacological understanding of receptor regulation, as well as signal formation and transduction \([64,65]\).

By investigating a large set of standard ligands, we demonstrated the usefulness of the mini-G sensor to reliably characterize agonists and antagonists. In our system, all four histamine receptor subtypes were constitutively active, although to a lesser extent than reported in other recombinant systems with the H\(_4\)R \([46,60]\). The occurrence of such constitutively active receptors depends on the expression levels and the stoichiometry of the GPCRs and the G proteins according to the extended ternary complex (ETC) model of GPCR function \([66]\). Thus, the applied test system limits the detectability of the constitutive activity and the extent of the inverse efficacy of a ligand \([67]\). In future routine characterization of histamine receptor ligands, it would be convenient to introduce a reference ligand that produces inverse deflection of bioluminescence in the mini-G protein recruitment assay, such as diphenhydramine (H\(_1\)R), famotidine (H\(_2\)R) and thioperamide (H\(_3\)R, H\(_4\)R).

In the literature, two models of the GPCR-G protein interaction are discussed: a collision coupling, and a pre-coupled model \([19,20,63]\). In the case of the H\(_2\)R, the lower the gene dose of the mGs, the higher the dynamic range. Further, we observed a high affinity binding site for the agonist histamine subject to the mGs expression level in radioligand competition binding experiments. Both results agreed with the collision coupling model of GPCR-G protein interaction, which supports an increased constitutive activity of GPCRs highly expressed in recombinant systems \([19,63]\). Therefore, it was not surprising that we did not detect such correlation for the H\(_1\)R and H\(_3\)R. Both receptors were expressed to a lesser extent compared to the H\(_2\)R (Supplementary Table S1) and also the expression level of mGsq was considerably lower compared to mGs (Supplementary Figure S5).

Concisely, this study describes the establishment and usefulness of a mini-G sensor for prospective drug discovery at the histamine receptors. Due to the homogenous nature and the non-radioactive readout with an, per definition, excellent dynamic range (Z’ factor), this assay will be automatable, and should be compatible with HTS.

4. Materials and Methods

4.1. Materials

Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Sigma-Aldrich (Taufkirchen, Germany) and Leibovitz’ L-15 medium (L-15) from Fisher Scientific (Niddereau, Germany). FBS, trypsin/EDTA and geneticin (G418) were from Merck Biochrom (Darmstadt, Germany), whereas puromycin was from InvivoGen (Toulouse, France) and furimazine from Promega (Mannheim, Germany). The pcDNA3.1 vector was from Thermo Scientific (Niddereau, Germany) and the pIRESpuro3 vector was a kind gift from Prof. Dr. Gunter Meister (University of Regensburg). Histamine dihydrochloride (his) was purchased from Tokyo Chemical Industry (Eschborn, Germany), whereas 4-methylhistamine dihydrochloride (4mhis), mepyramine maleate (mep), imetit dihydrobromide (imet), immeip dihydrobromide (immep), thioperamide maleate (thio), clobenpropit dihydrobromide (clob) and A943931 dihydrochloride (A943931) were from Tocris Bioscience (Bristol, United Kingdom). N\(^\alpha\)-methylhistamine dihydrochloride (Namh), betahistine dihydrochloride (betahis), diphenhydramine hydrochloride (dph), maprotiline hydrochloride (map), cyproheptadine hydrochloride sesquihydrate (cyp), amthamine dihydrobromide (amt), dimaprit dihydrochloride (dim), cimetidine (cim), famotidine (fam) and ranitidine hydrochloride (ran) were purchased from Sigma. Histaprodifen \([68]\) (histapro), suprahistaprodifen \([68]\) (suprahis), UR-KUM530 \([12]\) (KUM530), impromidine \([69]\) (impro), UR-PL294 \([49]\) (PL294), VUF8430 \([55]\) (VUF8430)
and JNJ7777120 [70] (JNJ) were synthesized in-house according to published procedures. Pitolisant hydrochloride (pito) was kindly provided by Prof. Dr. Katarzyna Kiec-Kononowicz (Jagiellonian University, Krakow). All ligands were dissolved, according to their physicochemical properties. Preferably, the ligands were dissolved in Millipore water, except for histaprodifen (histapro), suprahistaprodifen (suprahis), maprotiline (map), cimetidine (cim) and famotidine (fam). In these cases, DMSO (Merck) was (proportionally) used as solvent (DMSO/H$_2$O: histapro, suprahis: 50/50; map: 30/70; cim, fam: 100% DMSO).

4.2. Molecular Cloning

The human codon-optimized cDNA fragments encoding the mini-G proteins mGs, mGsi and mGsq (corresponding to mini-Gs393, mini-Gs/i43 and mini-Gs/q71 published by Nehmé [22], Supplementary Figure S1), were synthesized by Eurofins Genomics (Eurofins Genomics LLC, Ebersberg, Germany). Plasmids containing the split-NanoLuc fragments (NlucN, 159 amino acids; NlucC, 11 amino acids) were from Promega and cDNAs encoding the histamine receptors were purchased from the Missouri cDNA research center (Rolla, MO, USA). All cDNAs were amplified by PCR and subcloned into vector backbones by standard molecular cloning techniques. For this purpose, a set of pIRESpuro3 vectors was generated encoding the respective mini-G protein, which was N-terminally fused to the large split-luciferase fragment (NlucN) separated by a flexible glycine-serine-linker (encoding -GSSGGGSSGGGGSS-). The sequence encoding the H$_1$R-NlucC described by Littmann et al. (2019) was subcloned into pcDNA3.1 using the restriction enzymes HinDIII and SceII, and the receptor sequence was then replaced by either the H$_2$R, H$_3$R or H$_4$R gene using HinDIII and XbaI [71]. The optimal arrangement of a split-luciferase system to study the interaction of GPCRs and intracellular proteins of interest (GPCR-NlucC and NlucN-protein) was reported previously [23,71]. Plasmid DNA was quantified by UV-Vis absorbance using a NanoDrop spectrophotometer (ThermoFisher, Braunschweig, Germany). All sequences were verified by sequencing performed by Eurofins Genomics.

4.3. Cell Culture

HEK293T cells were a kind gift from Prof. Dr. Wulf Schneider (Institute for Medical Microbiology and Hygiene, Regensburg, Germany) and cultured in DMEM supplemented with 10% FBS at 37°C in a water-saturated atmosphere containing 5% CO$_2$. Cells were periodically inspected for mycoplasma contamination by means of the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany) and proven negative.

4.4. Generation of Stable Transfectants

In order to generate stable cell lines, wildtype HEK293T cells were stepwise transfected with a pIRESpuro3 vector encoding either the NlucN-mGs, -mGsi or -mGsq protein, and with the respective pcDNA3.1 plasmid encoding the histamine H$_{1-4}$ receptor-NlucC fusion protein according to the XtremeGene HP transfection protocol (Merck). The cells were then cultured in DMEM supplemented with 10% FBS, 1 µg/mL puromycin and 600 µg/mL G418 for sustained selection pressure.

4.5. Generation of Transient Transfectants

Adjusted to a cell density of 0.3 × 10$^6$ cells/mL, HEK293T cells were seeded into a 6-well cell culture plate (Sarstedt, Nürnberg, Germany) and allowed to attach overnight. The next day, the cells were transfected using linear polyethyleneimine (PEI, 1 mg/mL in PBS; 1:5 ratio (2 µg DNA: 10 µL PEI)) and incubated for another 48 h to allow for adequate protein expression. For mini-G protein recruitment assays and radioligand competition binding experiments, we applied a constant amount of 2 µg of total DNA per 6-well (total volume of 2 mL) comprising 1 µg of pcDNA3.1 H$_{2/3}$R-NlucC and increasing amounts of the pIRESpuro3 NlucN-m/Gsq/mGs/mGsi DNA (0.125, 0.25, 0.5, or 1.0 µg). To ensure a uniform transfection efficiency, the empty pIRESpuro3 vector was co-transfected as mock DNA (0.875, 0.75, 0.5 µg or none). For Western blot analysis of the mini-G protein expression, the cells were
transfected with a total amount of 2 µg DNA comprising 0.125, 0.25, 0.5 or 1.0 µg of the pIRESpuro3 NlucN-m/Gsq/mGs/mGsi and 1.875, 1.750, 1.5 and 1.0 µg, respectively, of the empty pIRESpuro3 vector as mock DNA.

4.6. Western Blot Analysis

Cells were lysed using a RIPA lysis buffer (50 mM Tris, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% Triton X-100, 150 mM NaCl) supplemented with SIGMAFAST protease inhibitor cocktail tablets according to the manufacturer's protocol (Sigma-Aldrich). Lysates (15 µg protein) and 10 µL of the Precision Plus Protein Dual Color Standard (Bio-Rad, Feldkirchen, Germany) were loaded to an 8–16% Novex Tris-glycine polyacrylamide gel (Thermo Scientific) and SDS-page was performed at 225 V for 1 h. Thereafter, the proteins were blotted on a nitrocellulose membrane (0.2 µ, 1 h). By incubation with 5% skim milk powder in phosphate-buffered saline supplemented with 0.05% Tween 20 (PBS-T) for 1 h at RT, nonspecific binding sites of the membrane were blocked. After three washing steps with PBS-T, blots were incubated overnight at 4 °C with the primary antibodies α-Nluc (1:5000; in PBS-T; polyclonal, produced in rabbit, kindly provided by Promega) and α-vinculin (1:500; in PBS-T; monoclonal; MAB6896, produced in mouse, R&D Systems Inc., MN, USA). After additional three washing steps on the next day, the membranes were incubated with the HRP-conjugated secondary antibodies (raised against IgG, respectively) α-rabbit (1:10,000 in PBS-T; sc-2313, produced in donkey, Santa Cruz, TX, USA) and α-mouse (1:100,000 in PBS-T; A0168, produced in goat; Sigma-Aldrich) for 3 h at RT. The blots were washed three times with PBS-T and developed using the Clarity Western ECL substrate (Bio-Rad, Feldkirchen, Germany). Subsequently, the colorimetric and luminescent images of the stained blots were captured using a ChemiDoc MP imager (Bio-Rad).

4.7. Mini-G Protein Recruitment Assay

The day before the experiment, cells were detached by trypsinization (0.05% trypsin, 0.02% EDTA in PBS) and centrifuged (700 g, 5 min). Subsequently, the cells were resuspended in L-15 supplemented with 10 mM HEPES (Serva, Heidelberg, Germany) and 5% FBS. Thereafter, 100,000 cells per well were seeded onto a white flat-bottom 96-well microtiter plate (Cat. No. 781965, Brand GmbH + CoKG, Wertheim, Germany) and incubated at 37 °C in a water-saturated atmosphere without additional CO₂ overnight. Shortly before the experiment, the substrate furimazine was diluted in L-15 and 10 µL were added to the cells (final dilution 1:1000). Then, the plate was transferred to a pre-heated (37 °C) EnSpire plate reader (Perkin Elmer Inc., Rodgau, Germany). After recording the basal luminescence for 15 min, 10 µL of the agonist serial dilutions were added to the cells (final volume: 100 µL) and luminescence traces were recorded for 45 min (agonist mode). When investigating antagonists, the antagonist dilutions were added before the reference agonist histamine (EC₅₀ concentration; H₁R: 10 µM, H₂–H₄R: 1 µM) and the cells were incubated for 15 min (antagonist mode). Luminescence was captured with an integration time of 0.1 s per well. Data were analyzed using GraphPad Prism8 software (San Diego, CA, USA). The relative luminescence units (RLU) were corrected for (slight) inter-well variation caused by differences in cell density and substrate concentration, as well as for baseline drift, by dividing all data by the mean luminescence intensity of the respective L-15 control. AUCs of the luminescence traces for each concentration were calculated and normalized to the maximum response of 100 µM histamine (100% control) and L-15 (0% control). The logarithmic ligand concentrations were fitted against the normalized intensities with variable slope (log(c) vs. response–variable slope (four parameters)). The fit yielded pEC₅₀ and E₅₀ values in the case of agonists, and pIC₅₀ values in the case of antagonists, which were used to calculate pKᵦ values according to the Cheng-Prusoff-equation [72]. In order to assess Z' factors, the baseline-corrected relative luminescence units (RLU) of 100 µM histamine and L-15 were inter-well corrected and AUCs were used for the calculation of means and standard deviations [34].
Significant differences in the efficacies obtained in the mini-G protein recruitment assay were assessed using a one-sample t-test (\( n = 5; \alpha = 0.05 \)). When investigating the influence of the mini-G protein expression level, significant differences between AUCs and pEC\(_{50}\) values were calculated using one-way ANOVA followed by Tukey’s multiple comparison test (\( n = 5; \alpha = 0.05 \)).

4.8. Radioligand Binding Experiments

Radioligand saturation binding experiments were performed using intact HEK293T cells co-expressing either NlucN-mGsq/H\(_2\)R-NlucC, NlucN-mGs/H\(_2\)R-NlucC, NlucN-mGsi/H\(_3\)R-NlucC or NlucN-mGsi/H\(_4\)R-NlucC. The following radioligands were used to verify the receptor expressions: \({}^3\text{H}\text{mepyramine (a}_s = 20 \text{Ci/mM, Hartmann Analytics GmbH, Braunschweig, Germany)}\) for the H\(_1\)R, \({}^3\text{H}\text{UR-DE257 [52] (a}_s = 32.9 \text{Ci/mmol) for the H}_2\text{R and [}^3\text{H}\text{UR-PI294 [57] (a}_s = 93.3 \text{Ci/mmol) for the H}_3\text{R and H}_4\text{R. The specific binding of each radioligand was determined by subtracting the non-specific binding from the corresponding total binding. The cells were incubated with various concentrations of the radioligands in the absence (L-15) (total binding) or presence of a competitor at a final concentration of 10 \mu M (nonspecific binding). As competitors, we applied diphenhydramine for the H\(_1\)R, famotidine for the H\(_2\)R, thioperamide for the H\(_3\)R or histamine for the H\(_4\)R. Radioligand competition binding experiments were performed using intact HEK293T cells expressing the NlucN-mGs and H\(_2\)R-NlucC fusion proteins. The cells were incubated with 50 nM [\(^3\text{H}\text{UR-DE257 and with the ligands in serial dilution and with L-15 (negative control). The non-specific binding of the radioligand was determined in the presence of famotidine at a final concentration of 10 \mu M and subtracted from all values. For both, radioligand saturation and competition binding experiments, all (radio)ligand dilutions were prepared 10-fold concentrated in L-15 and 10 \mu L/well were transferred to a round bottom polypropylene 96-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). The cells were detached by trypsinization (0.05% trypsin + 0.02% EDTA), harvested by centrifugation (700 g, 5 min) and resuspended in L-15. The cells were adjust-ed to a density of 1.0×10^6 cells/mL and 80 \mu L of the cell suspension were added to each well (final assay volume of 100 \mu L). Then, the cells were incubated at room temperature under shaking for 60–120 min, and the cells were collected by filtration and washed with ice-cold PBS using a 96-well harvester (Brandel Inc., Unterföhring, Germany). The cell-associated radioactivity was measured by liquid scintillation counting, as previously described [73].

All data were analyzed using GraphPad Prism8 software. In the case of saturation binding experiments, all data were best fitted to a one-site saturation binding model (one site—total and nonspecific binding; one site—specific binding) yielding \( K_d \) values. For competition binding experiments, data of the agonist histamine were best fitted to a two-sites competition binding model (two sites—fit \( \log IC_{50} \) yielding \( pIC_{50,\text{high}} \) and \( pIC_{50,\text{low}} \). Except, competition binding data of histamine using cells transiently transfected with the H\(_2\)R alone and data of the antagonist famotidine obtained at cells stably co-expressing the H\(_2\)R and mGs were fitted to the one-site three parameter logistic fit (one-site—fit \( \log IC_{50} \)) to determine \( pIC_{50} \) values. Obtained \( pIC_{50} \) values (\( pIC_{50}, pIC_{50,\text{high}}, pIC_{50,\text{low}} \)) were then used to calculate \( pK_b \) values according to the Cheng-Prusoff-equation [72].

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/22/8440/s1.

Author Contributions: Conceptualization, C.H. and L.G.; methodology, C.H., U.S.; validation, C.H.; formal analysis, C.H.; investigation, C.H., U.S., K.T., and D.M.; resources, S.P. (Sebastian Pitzl), S.P. (Steffen Pockes) and A.S.; data curation, C.H.; writing—original draft preparation, C.H. and S.P. (Steffen Pockes); writing—review and editing, C.H., U.S., K.T., L.G., D.M., S.P. (Sebastian Pitzl), G.B., S.P. (Steffen Pockes), and A.S.; visualization, C.H. and L.G.; supervision, G.B., S.P. (Steffen Pockes) and A.S.; project administration, C.H.; funding acquisition, A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the DFG, Graduate Training Programme (Graduiertenkolleg) 1910.

Acknowledgments: We are grateful to Timo Littmann and Laura Humphrys for constructive discussion as well as to Maria Beer-Krön and Valerie Huber for expert technical assistance.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

H1R Human histamine H1 receptor
H2R Human histamine H2 receptor
H3R Human histamine H3 receptor
H4R Human histamine H4 receptor
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
L-15 Leibovitz’ L-15 medium
NanoLuc NanoLuc luciferase

References

1. Hamm, H.E. How activated receptors couple to g proteins. Proc. Natl. Acad. Sci. USA 2001, 98, 4819–4821. [CrossRef] [PubMed]
2. Milligan, G.; Kostenis, E. Heterotrimeric g-proteins: A short history. Br. J. Pharmacol. 2006, 147 (Suppl. 1), S46–S55. [CrossRef]
3. Gutowski, S.; Smrcka, A.; Nowak, L.; Wu, D.G.; Simon, M.; Sternweis, P.C. Antibodies to the alpha q subfamily of guanine nucleotide-binding regulatory protein alpha subunits attenuate activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by hormones. J. Biol. Chem. 1991, 266, 20519–20524. [PubMed]
4. Dowal, L.; Provitera, P.; Scarlata, S. Stable association between g alpha(q) and phospholipase c beta 1 in living cells. J. Biol. Chem. 2006, 281, 23999–24014. [CrossRef] [PubMed]
5. Sunahara, R.K.; Insel, P.A. The molecular pharmacology of g protein signaling then and now: A tribute to alfred g. Gilman. Mol. Pharmacol. 2016, 89, 585–592. [CrossRef] [PubMed]
6. Lazar, A.M.; Irannejad, R.; Baldwin, T.A.; Sundaram, A.B.; Gutkind, J.S.; Inoue, A.; Dessauer, C.W.; Von Zastrow, M. G protein-regulated endocytic trafficking of adenylyl cyclase type 9. Elife 2020, 9, e58039. [CrossRef]
7. Hauser, A.S.; Attwood, M.M.; Rask-Andersen, M.; Schioth, H.B.; Gloriam, D.E. Trends in gpcr drug discovery: New agents, targets and indications. Nat. Rev. Drug Discov. 2017, 16, 829–842. [CrossRef]
8. Schnell, D.; Burleigh, K.; Trick, J.; Seifert, R. No evidence for functional selectivity of proxyfan at the human histamine h3 receptor coupled to defined gi/go protein heterotrimers. J. Pharmacol. Exp. Ther. 2010, 332, 996–1005. [CrossRef]
9. Wifling, D.; Loffel, K.; Nordemann, U.; Strasser, A.; Bernhardt, G.; Dove, S.; Seifert, R.; Buschauer, A. Molecular determinants for the high constitutive activity of the human histamine h4 receptor: Functional studies on orthologues and mutants. Br. J. Pharmacol. 2015, 172, 785–798. [CrossRef]
10. Bongers, G.; Krueger, K.M.; Miller, T.R.; Baranowski, J.L.; Estvander, B.R.; Witte, D.G.; Strakhova, M.I.; van Meer, P.; Bakker, R.A.; Cowart, M.D.; et al. An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine h3 isoform confers pharmacological differences and constitutive activity. J. Pharmacol. Exp. Ther. 2007, 323, 888–898. [CrossRef]
11. Preuss, H.; Ghorai, P.; Kraus, A.; Dove, S.; Buschauer, A.; Seifert, R. Constitutive activity and ligand selectivity of human, guinea pig, rat, and canine histamine h2 receptors. J. Pharmacol. Exp. Ther. 2007, 321, 983–995. [CrossRef] [PubMed]
12. Strasser, A.; Striegl, B.; Wittmann, H.J.; Seifert, R. Pharmacological profile of histaprodifens at four recombinant histamine h1 receptor species isoforms. J. Pharmacol. Exp. Ther. 2008, 324, 60–71. [CrossRef] [PubMed]
13. Seifert, R.; Wenzel-Seifert, K.; Gether, U.; Kobilka, B.K. Functional differences between full and partial agonists: Evidence for ligand-specific receptor conformations. J. Pharmacol. Exp. Ther. 2001, 297, 1218–1226. [PubMed]
14. Koval, A.; Kopein, D.; Purvanov, V.; Katanaev, V.L. Europium-labeled gtp as a general nonradioactive substitute for [(35)s]gtpgammas in high-throughput g protein studies. Anal. Biochem. 2010, 397, 202–207. [CrossRef]
15. Anderson, E.K.; Martin, D.S. A fluorescent gtp analog as a specific, high-precision label of microtubules. *Biotechniques* **2011**, *51*, 43–48. [CrossRef]

16. Mondal, S.; Hsiao, K.; Goueli, S.A. A homogenous bioluminescent system for measuring gtpase, gtpase activating protein, and guanine nucleotide exchange factor activities. *Assay Drug Dev. Technol.* **2015**, *13*, 444–455. [CrossRef]

17. Strange, P.G. Use of the gtpgammas ([35s]gtpgammas and eu-gtpgammas) binding assay for analysis of ligand potency and efficacy at g protein-coupled receptors. *Br. J. Pharmacol.* **2010**, *161*, 1238–1249. [CrossRef]

18. Denis, C.; Sauliere, A.; Galandrin, S.; Senard, J.M.; Gales, C. Probing heterotrimeric g protein activation: Applications to biased ligands. *Curr. Pharm. Des.* **2012**, *18*, 128–144. [CrossRef]

19. Hein, P.; Frank, M.; Hoffmann, C.; Lohse, M.J.; Bunemann, M. Dynamics of receptor/g protein coupling in living cells. *EMBO J.* **2005**, *24*, 4106–4114. [CrossRef]

20. Gales, C.; Van Durm, J.J.; Schaak, S.; Percherancier, Y.; Audet, M.; Paris, H.; Bouvier, M. Probing the activation-promoted structural rearrangements in preassembled receptor-g protein complexes. *Nat. Struct. Mol. Biol.* **2006**, *13*, 778–786. [CrossRef]

21. Mocking, T.A.M.; Buzink, M.; Leurs, R.; Vischer, H.F. Bioluminescence resonance energy transfer based g protein-activation assay to probe duration of antagonism at the histamine h3 receptor. *Int. J. Mol. Sci.* **2019**, *20*, 3724. [CrossRef] [PubMed]

22. Nehme, R.; Carpenter, B.; Singhal, A.; Edwards, P.C.; White, C.F.; Du, H.; Griesshammer, R.; Tate, C.G. Mini-g proteins: Novel tools for studying gpcrs in their active conformation. *PLoS ONE* **2017**, *12*, e0175642. [CrossRef] [PubMed]

23. Wan, Q.; Okashah, N.; Inoue, A.; Nehme, R.; Carpenter, B.; Tate, C.G.; Lambert, N.A. Mini g protein probes for active g protein-coupled receptors (gpcrs) in live cells. *J. Biol. Chem.* **2018**, *293*, 7466–7473. [CrossRef] [PubMed]

24. Wouters, E.; Marin, A.R.; Dalton, J.A.R.; Giraldo, J.; Stove, C. Distinct dopamine d(2) receptor antagonists differentially impact d(2) receptor oligomerization. *Int. J. Mol. Sci.* **2019**, *20*, 1686. [CrossRef]

25. Wouters, E.; Walraed, J.; Robertson, M.J.; Meyrath, M.; Szpakowska, M.; Chevigne, A.; Skiniotis, G.; Tate, C. Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. *ACS Pharmacol. Transl. Sci.* **2020**, *3*, 285–295. [CrossRef]

26. Pottie, E.; Tosh, D.K.; Gao, Z.G.; Jacobson, K.A.; Stove, C.P. Assessment of biased agonism at the a3 adenosine receptor using beta-arrestin and minigalphai recruitment assays. *Biochem. Pharmacol.* **2020**, *177*, 113934. [CrossRef]

27. Pottie, E.; Dedecker, P.; Stove, C.P. Identification of psychedelic new psychoactive substances (nps) showing biased agonism at the 5-htr2ar through simultaneous use of beta-arrestin 2 and minigalphaq bioassays. *Biochim. Pharmacol.* **2020**, *182*, 114251. [CrossRef]

28. Abiuso, A.M.B.; Varela, M.L.; Haro Durand, L.; Besio Moreno, M.; Marcos, A.; Ponzio, R.; Rivarola, M.A.; Belgorosky, A.; Fignataro, O.P.; Berensztein, E.; et al. Histamine h4 receptor as a novel therapeutic target for the treatment of leydig-cell tumours in prepubertal boys. *Eur. J. Cancer* **2018**, *81*, 125–135. [CrossRef]

29. Dixon, A.S.; Schwinn, M.K.; Hall, M.P.; Zimmermann, K.; Otto, P.; Lubben, T.H.; Butler, B.L.; Binkowski, B.F.; Machleidt, T.; Kirkland, T.A.; et al. Nanoluc complementation reporter optimized for accurate measurement of protein interactions in cells. *ACS Chem. Biol.* **2016**, *11*, 400–408. [CrossRef]

30. Ayoub, M.A.; Landiomiel, F.; Gallay, N.; Jegot, G.; Poupon, A.; Crepieux, P.; Reiter, E. Assessing gonadotropin receptor function by resonance energy transfer-based assays. *Front. Endocrinol. (Lausanne)* **2015**, *6*, 130. [CrossRef]

31. Perkovska, S.; Mjejean, C.; Ayoub, M.A.; Li, J.; Hemery, F.; Corbani, M.; Laguette, N.; Ventura, M.A.; Orcel, H.; Durroux, T.; et al. V1b vasopressin receptor trafficking and signaling: Role of arrests, g proteins and src kinase. *Traffic* **2018**, *19*, 58–82. [CrossRef] [PubMed]

32. Copeland, R.A. The drug-target residence time model: A 10-year retrospective. *Nat. Rev. Drug Discov.* **2016**, *15*, 87–95. [CrossRef] [PubMed]

33. Hoffmann, C.; Castro, M.; Rinken, A.; Leurs, R.; Hill, S.J.; Vischer, H.F. Ligand residence time at g-protein-coupled receptors-why we should take our time to study it. *Mol. Pharmacol.* **2015**, *88*, 552–560. [CrossRef] [PubMed]

34. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen.* **1999**, *4*, 67–73. [CrossRef]
35. Mocking, T.A.M.; Verweij, E.W.E.; Vischer, H.F.; Leurs, R. Homogeneous, real-time nanobret binding assays for the histamine h3 and h4 receptors on living cells. *Mol. Pharmacol.* 2018, 94, 1371–1381. [CrossRef]

36. Bartole, E.; Littmann, T.; Tanaka, M.; Ozawa, T.; Buschauer, A.; Bernhardt, G. [(3)h]ur-deba176: A 2,4-diaminopyrimidine-type radioligand enabling binding studies at the human, mouse, and rat histamine h4 receptors. *J. Med. Chem.* 2019, 62, 8338–8356. [CrossRef]

37. Schihada, H.; Ma, X.; Zabel, U.; Vischer, H.F.; Schulte, G.; Leurs, R.; Pockes, S.; Lohse, M.J. Development of a conformational histamine h3 receptor biosensor for the synchronous screening of agonists and inverse agonists. *Acs Sers. 2020*, 5, 1734–1742. [CrossRef]

38. Schrage, R.; De Min, A.; Hochheiser, K.; Mohr, K. Superagonism at g protein-coupled receptors and beyond. *Br. J. Pharmacol.* 2016, 173, 3018–3027. [CrossRef]

39. Lieb, S.; Littmann, T.; Plank, N.; Felixberger, J.; Tanaka, M.; Schafer, T.; Krief, S.; Elz, S.; Friedland, K.; Bernhardt, G.; et al. Label-free versus conventional cellular assays: Functional investigations on the human histamine h1 receptor. *Pharmacol. Res.* 2016, 114, 13–26. [CrossRef]

40. Strasser, A.; Wittmann, H.J.; Kunze, M.; Elz, S.; Seifert, R. Molecular basis for the selective interaction of synthetic agonists with the human histamine h1-receptor compared with the guinea pig h1-receptor. *Mol. Pharmacol.* 2009, 75, 454–465. [CrossRef]

41. Costa, T.; Herz, A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to gtp-binding proteins. *Proc. Natl. Acad. Sci. USA* 1989, 86, 7321–7325. [CrossRef] [PubMed]

42. Smit, M.J.; Leurs, R.; Alewijnse, A.E.; Blauw, J.; Van Nieuw Amerongen, G.P.; Van De Vrede, Y.; Roovers, E.; Timmerman, H. Inverse agonism of histamine h2 antagonist accounts for upregulation of spontaneously active histamine h2 receptors. *Proc. Natl. Acad. Sci. USA* 1996, 93, 6802–6807. [CrossRef] [PubMed]

43. Bakker, R.A.; Wieland, K.; Timmerman, H.; Leurs, R. Constitutive activity of the histamine h(1) receptor reveals inverse agonism of histamine h(1) receptor antagonists. *Eur. J. Pharmacol.* 2000, 387, R5–R7. [CrossRef]

44. Alewijnse, A.E.; Smit, M.J.; Hoffmann, M.; Verzijl, D.; Timmerman, H.; Leurs, R. Constitutive activity and structural instability of the wild-type human h2 receptor. *J. Neurochem.* 1998, 71, 799–807. [CrossRef]

45. Diaz Nebreda, A.; Zappia, C.D.; Rodriguez Gonzalez, A.; Sahores, A.; Sosa, M.; Burghi, V.; Monczor, F.; Davio, C.; Fernandez, N.; Shayo, C. Involvement of histamine h1 and h2 receptor inverse agonists in receptor’s crossregulation. *Eur. J. Pharmacol.* 2019, 847, 42–52. [CrossRef]

46. Wifling, D.; Bernhardt, G.; Dove, S.; Buschauer, A. The extracellular loop 2 (ecl2) of the human histamine h4 receptor substantially contributes to ligand binding and constitutive activity. *PLoS ONE* 2015, 10, e0117185. [CrossRef]

47. Seifert, R.; Wenzel-Seifert, K.; Burckstummer, T.; Pertz, H.H.; Schunack, W.; Dove, S.; Buschauer, A.; Elz, S. Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine h1-receptor. *J. Pharmacol. Exp. Ther.* 2003, 305, 1104–1115. [CrossRef]

48. Igel, P.; Geyer, R.; Strasser, A.; Dove, S.; Seifert, R.; Buschauer, A. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine h4 receptor agonists. *J. Med. Chem.* 2009, 52, 6297–6313. [CrossRef]

49. Igel, P.; Schneider, E.; Schnell, D.; Elz, S.; Seifert, R.; Buschauer, A. N(g)-acylated imidazolylpropylguanidines as potent histamine h4 receptor agonists: Selectivity by variation of the n(g)-substituent. *J. Med. Chem.* 2009, 52, 6263–6272. [CrossRef]

50. Appl, H.; Holzammer, T.; Dove, S.; Haen, E.; Strasser, A.; Seifert, R. Interactions of recombinant human histamine h(1)r, h(2)r, h(3)r, and h(4)r receptors with 34 antidepressants and antipsychotics. *Naunyn Schmiedebergs. Arch. Pharmacol.* 2012, 385, 145–170. [CrossRef]

51. Bakker, R.A.; Schoonuis, S.B.; Smit, M.J.; Timmerman, H.; Leurs, R. Histamine h(1)-receptor activation of nuclear factor-kappa b: Roles for g beta gamma- and g alpha(q)-subunits in constitutive and agonist-mediated signaling. *Mol. Pharmacol.* 2001, 60, 1133–1142. [CrossRef] [PubMed]

52. Baumeister, P.; Erdmann, D.; Biselli, S.; Kagermeier, N.; Elz, S.; Bernhardt, G.; Buschauer, A. [(3)h]ur-de257: Development of a tritium-labeled squaramide-type selective histamine h2 receptor antagonist. *ChemMedChem* 2015, 10, 83–93. [CrossRef] [PubMed]

53. Leurs, R.; Smit, M.J.; Menge, W.M.; Timmerman, H. Pharmacological characterization of the human histamine h2 receptor stably expressed in Chinese hamster ovary cells. *Br. J. Pharmacol.* 1994, 112, 847–854. [CrossRef] [PubMed]
54. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; Buschauer, A. Luciferase reporter
55. Lim, H.D.; van Rijn, R.M.; Ling, P.; Bakker, R.A.; Thurmond, R.L.; Leurs, R. Evaluation of histamine h1-, h2-, and h3-receptor ligands at the human histamine h4 receptor: Identification of 4-methylhistamine as the first potent and selective h4 receptor agonist. J. Pharmacol. Exp. Ther. 2005, 314, 1310–1321. [CrossRef] [PubMed]
56. Ilyaskina, O.S.; Lemoine, H.; Bünemann, M. Lifetime of muscarinic receptor–g-protein complexes determines the activity state of the human histamine h4-receptor. Biochemistry 2009, 48, 1424–1438. [CrossRef]
57. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; Buschauer, A. Luciferase reporter gene assay on human, murine and rat histamine h4 receptor orthologs: Correlations and discrepancies between distal and proximal readouts. Proc. Natl. Acad. Sci. USA 2009, 106, 9885–9890. [CrossRef] [PubMed]
58. Cowart, M.D.; Altenbach, R.J.; Liu, H.; Hsieh, G.C.; Drizin, I.; Milicic, I.; Miller, T.R.; Witte, D.G.; Wishart, N.; Fix-Stenzel, S.R.; et al. The first potent and selective non-imidazole human histamine h4 receptor antagonists. J. Med. Chem. 2008, 51, 6547–6557. [CrossRef] [PubMed]
59. Tolkovsky, A.M.; Levitzki, A. Mode of coupling between the beta-adrenergic receptor and adenylate cyclase in turkey erythrocytes. Biochemistry 1978, 17, 3795. [CrossRef] [PubMed]
60. Schneider, E.H.; Schnell, D.; Papa, D.; Seifert, R. High constitutive activity and a g-protein-independent high-affinity state of the human histamine h4-receptor. Biochemistry 2009, 48, 1424–1438. [CrossRef]
61. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; Buschauer, A. Luciferase reporter gene assay on human, murine and rat histamine h4 receptor orthologs: Correlations and discrepancies between distal and proximal readouts. Proc. Natl. Acad. Sci. USA 2009, 106, 9885–9890. [CrossRef] [PubMed]
62. Cowart, M.D.; Altenbach, R.J.; Liu, H.; Hsieh, G.C.; Drizin, I.; Milicic, I.; Miller, T.R.; Witte, D.G.; Wishart, N.; Fix-Stenzel, S.R.; et al. Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: A new class of histamine h4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J. Med. Chem. 2008, 51, 6547–6557. [CrossRef] [PubMed]
63. Tolkovsky, A.M.; Levitzki, A. Mode of coupling between the beta-adrenergic receptor and adenylate cyclase in turkey erythrocytes. Biochemistry 1978, 17, 3795. [CrossRef] [PubMed]
64. Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; Buschauer, A. Luciferase reporter gene assay on human, murine and rat histamine h4 receptor orthologs: Correlations and discrepancies between distal and proximal readouts. Proc. Natl. Acad. Sci. USA 2009, 106, 9885–9890. [CrossRef] [PubMed]
65. Ilyaskina, O.S.; Lemoine, H.; Bünemann, M. Lifetime of muscarinic receptor–g-protein complexes determines coupling efficiency and g-protein subtype selectivity. Proc. Natl. Acad. Sci. USA 2008, 115, 5016–5021. [CrossRef]
66. Samama, P.; Cotechia, S.; Costa, T.; Lefkowitz, R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 1993, 268, 4625–4636. [CrossRef] [PubMed]
67. Kenakin, T. Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 2004, 65, 2–11. [CrossRef]
68. Elz, S.; Kramer, K.; Pertz, H.H.; Detert, H.; Ter Laak, A.M.; Kuhne, R.; Schunack, W. Histaprodifens: Synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine h(1)-receptor agonists. J. Med. Chem. 2000, 43, 1071–1084. [CrossRef]
69. Durant, G.J.; Ganellin, C.R.; Hills, D.W.; Miles, P.D.; Parsons, M.E.; Pepper, E.S.; White, G.R. The histamine h2-receptor agonist impromidine: Synthesis and structure activity considerations. J. Med. Chem. 1985, 28, 1414–1422. [CrossRef]
70. Jablonowski, J.A.; Grice, C.A.; Chai, W.; Dvorak, C.A.; Venable, J.D.; Kwok, A.K.; Ly, K.S.; Wei, J.; Baker, S.M.; Desai, P.J.; et al. The first potent and selective non-imidazole human histamine h4 receptor antagonists. J. Med. Chem. 2003, 46, 3957–3960. [CrossRef]
71. Littmann, T.; Buschauer, A.; Bernhardt, G. Split luciferase-based assay for simultaneous analyses of the ligand concentration- and time-dependent recruitment of beta-arrestin2. Anal. Biochem. 2019, 573, 8–16. [CrossRef] [PubMed]
72. Cheng, Y.; Prusoff, W.H. Relationship between the inhibition constant (k1) and the concentration of inhibitor which causes 50 per cent inhibition (i50) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099–3108. [PubMed]

73. Kagermeier, N.; Werner, K.; Keller, M.; Baumeister, P.; Bernhardt, G.; Seifert, R.; Buschauer, A. Dimeric carbamoylguanidine-type histamine h2 receptor ligands: A new class of potent and selective agonists. *Bioorg. Med. Chem.* **2015**, *23*, 3957–3969. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).